Please login to the form below

Not currently logged in
Email:
Password:

Brintellix

This page shows the latest Brintellix news and features for those working in and with pharma, biotech and healthcare.

Lundbeck sways NICE with new Brintellix data

Lundbeck sways NICE with new Brintellix data

NICE has recommended Lundbeck's Brintellix for adults with major depressive order in final draft guidance. ... The submission included data from the REVIVE trial which compared Brintellix with Servier's Valdoxan (agomelatine).

Latest news

  • Lundbeck to cut 1,000 jobs in major restructure Lundbeck to cut 1,000 jobs in major restructure

    Lundbeck's focus will now turn more to its newer drugs such as Brintellix (vortioxetine), Northera (droxidopa), Onfi (clobazam) and Abilify Maintena (aripriprazole) which saw a 190% growth in sales.

  • US filing aims to elevate Brintellix above its competition US filing aims to elevate Brintellix above its competition

    US filing aims to elevate Brintellix above its competition. Drug looking for an edge in the highly competitive major depressive disorder market. ... Lundbeck and Takeda have filed for US approval of new labelling for their antidepressant Brintellix that

  • Lundbeck and Otsuka's Rexulti set for August launch in US Lundbeck and Otsuka's Rexulti set for August launch in US

    Meanwhile, Rexulti is one of string of new drugs at Lundbeck - along with the likes of long-acting aripiprazole depot Abilify Maintena (also partnered with Otsuka) and new antidepressant Brintellix (vortioxetine) -

  • Schultz takes Lundbeck helm after leaving Novo Nordisk Schultz takes Lundbeck helm after leaving Novo Nordisk

    120m kroner and antidepressant Brintellix (vortioxetine) adding another 98m kroner, up from 8m kroner a year ago. ... Brintellix has now been launched in 20 countries and while uptake is "still limited outside the Nordic countries and the Netherlands,"

  • Brintellix first antidepressant with cognition claim in Europe Brintellix first antidepressant with cognition claim in Europe

    Brintellix first antidepressant with cognition claim in Europe. Trial found it performed better than Lilly’ s rival Cymbalta. ... The Danish company also has a long-acting version of schizophrenia drug Abilify (aripiprazole) and alcohol addiction

More from news
Approximately 8 fully matching, plus 19 partially matching documents found.

Latest appointments

  • Bayer’s Barbara Jaszewski joins Lundbeck Bayer’s Barbara Jaszewski joins Lundbeck

    In addition, Lundbeck also has Brintellix (vortioxetine) under review by the EMA, while a once-monthly version of schizophrenia drug Abilify (aripiprazole) is also due to launch during 2013.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

How to get management buy-in for content marketing
Pharma content marketing is still fairly new in the scheme of things for the pharma industry. In the conservative and traditional pharma industry that’s fraught with regulations, getting management buy-in...
Paywatch and the market access waters
Understanding and responding to payers’ needs has become priority number one for pharma as it battles the choppy seas of the global health economy...
EY Life Sciences Sector Update
Asia-Pacific and Japan...

Infographics